GetTopicDetailResponse(id=180988e5793, topicName=蛋白質(zhì)降解劑, introduction=蛋白質(zhì)降解劑, content=null, image=null, comments=2, allHits=646, url=https://h5.medsci.cn/topic?id=88757, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=91457, tagList=[TagDto(tagId=91457, tagName=蛋白質(zhì)降解劑)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1811581, encodeId=717f181158169, content=<a href='/topic/show?id=180988e5793' target=_blank style='color:#2F92EE;'>#蛋白質(zhì)降解劑#</a>, objectTitle=Arvinas宣布啟動1期臨床研究，評估其靶向雌激素受體的PROTAC蛋白質(zhì)降解劑ARV-471治療乳腺癌的活性, objectType=article, longId=178296, objectId=d3011e8296df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3011e8296df, replyNumber=0, likeNumber=84, createdTime=2019-11-30, rootId=0, userName=qidongfanjian, userId=b09892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3011e8296df, moduleTitle=Arvinas宣布啟動1期臨床研究，評估其靶向雌激素受體的PROTAC蛋白質(zhì)降解劑ARV-471治療乳腺癌的活性, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=d3011e8296df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811580, encodeId=82e518115804b, content=<a href='/topic/show?id=180988e5793' target=_blank style='color:#2F92EE;'>#蛋白質(zhì)降解劑#</a>, objectTitle=Arvinas靶向雌激素受體的蛋白質(zhì)降解劑ARV-471治療乳腺癌，其IND申請獲FDA授權(quán), objectType=article, longId=172234, objectId=b4761e22346d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4761e22346d, replyNumber=0, likeNumber=96, createdTime=2020-04-06, rootId=0, userName=qidongfanjian, userId=b09892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4761e22346d, moduleTitle=Arvinas靶向雌激素受體的蛋白質(zhì)降解劑ARV-471治療乳腺癌，其IND申請獲FDA授權(quán), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=b4761e22346d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
